1. AB0892 Progressive clinical benefit in chronic refractory gout patients achieving a persistent urate lowering effect from pegloticase treatment. (15th June 2017) Authors: Khanna, P; Mandell, B; Fleischmann, R; Kay, J; Yeo, A; Lipsky, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0207 Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate, methotrexate alone or placebo: the dinora trial. (15th June 2017) Authors: Stamm, TA; Machold, K; Aletaha, D; Alasti, F; Lipsky, P; Pisetsky, D; Landewe, R; Heijde, D van der; Sepriano, A; Aringer, M; Boumpas, D; Burmester, G; Cutolo, M; Ebener, W; Graninger, W; Huizinga, T; Schett, G; Schulze-Koops, H; Tak, PP; Breedveld, F Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 560 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Issue 4 (24th August 2007) Authors: Sawalha, A H; Kaufman, K M; Kelly, J A; Adler, A J; Aberle, T; Kilpatrick, J; Wakeland, E K; Li, Q-Z; Wandstrat, A E; Karp, D R; James, J A; Merrill, J T; Lipsky, P; Harley, J B Journal: Annals of the rheumatic diseases Issue: Volume 67:Issue 4(2008) Page Start: 458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study. (21st March 2018) Authors: van Vollenhoven, R; Hahn, B; Tsokos, G; Wagner, C; Lipsky, P; Hsu, B; Chevrier, M; Gordon, R; Triebel, M; Rose, S Journal: Lupus science & medicine Issue: Volume 5(2018)Supplement 1 Page Start: A28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THU0416 Rapid tophus resolution in chronic refractory gout patients treated with pegloticase. (15th June 2017) Authors: Mandell, B; Yeo, A; Lipsky, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0438 Lack of predictive value of the NIAID/FAAN criteria to identify subjects with evidence of immune activation after receiving pegloticase for chronic refractory gout. (15th June 2017) Authors: Calabrese, L; Kavanaugh, A; Yeo, A; Lipsky, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0448 Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi: response to pegloticase. (15th June 2017) Authors: Edwards, NL; Singh, J; Troum, O; Yeo, A; Lipsky, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0449 Evidence based development of criteria for complete response in patients with chronic refractory gout. (15th June 2017) Authors: Schlesinger, N; Khanna, P; Yeo, A; Lipsky, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗